### Cytarabine

**Indication**
- Acute myeloid leukaemia with recurrent genetic abnormalities

**INN**
- Cytarabine

**Medicine type**
- Chemical agent

**List type**
- Complementary (EML)
- (EMLc)

**Formulations**
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial

**EML status history**
- First added in 1979 (TRS 641)
- Changed in 2015 (TRS 994)
- Changed in 2019 (TRS 1021)
- Changed in 2023 (TRS 1049)

**Sex**
- All

**Age**
- Also recommended for children

**Therapeutic alternatives**
- The recommendation is for this specific medicine

**Patent information**
- Patents have expired in most jurisdictions
- Read more about patents.

**Tags**

**Wikipedia**
- Cytarabine

**DrugBank**
- Cytarabine

### Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose form of cytarabine (100 mg/mL in vial) to the EML and EMLc.